Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: February 25, 2014
Context: This filing serves as a Director Declaration in conformity with Listing Rule 9.6.14, notifying the market of a change in directorship.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification and does not contain financial statements or performance data.
Material Changes
Director Appointment: Dr. Stephanie Burns, a Non-Executive Director of GSK, was appointed as a Director to the Board of Kellogg Company on February 25, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the appointment of Dr. Stephanie Burns to the Kellogg Company Board.
- Confirm compliance with Listing Rule 9.6.14 regarding director notifications.
- Note that this filing contains no financial performance data for the period.